

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Olaparib

INITIATION – Ovarian cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer

and

- ☐ There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation

and

- ☐ Patient has newly diagnosed, advanced disease
- and
- ☐ Patient has received one line** of previous treatment with platinum-based chemotherapy
- and
- ☐ Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen

or

- ☐ Patient has received at least two lines** of previous treatment with platinum-based chemotherapy
- and
- ☐ Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy
- and
- ☐ Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen
- and
- ☐ Patient has not previously received funded olaparib treatment

and

- ☐ Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen

and

- ☐ Treatment to be administered as maintenance treatment

and

- ☐ Treatment not to be administered in combination with other chemotherapy

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Olaparib - *continued*

CONTINUATION – Ovarian cancer

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- ☐ Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- ☐ Treatment remains clinically appropriate and patient is benefitting from treatment

and

- ☐ No evidence of progressive disease

or

- ☐ Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion

and

- ☐ Treatment to be administered as maintenance treatment

and

- ☐ Treatment not to be administered in combination with other chemotherapy

and

- ☐ Patient has received one line** of previous treatment with platinum-based chemotherapy

and

- ☐ Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years

or

- ☐ Patient has received at least two lines** of previous treatment with platinum-based chemotherapy

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.
**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

I confirm that the above details are correct:

Signed: Date: